Pharmacogenetic profiling in the treatment of heart disease

被引：6

作者：

Dorn, Gerald W., II ^{[1
]}

机构：

[1] Washington Univ, Sch Med, Dept Med, Ctr Pharmacogenom, St Louis, MO 63110 USA

来源：

TRANSLATIONAL RESEARCH | 2009年 / 154卷 / 06期

基金：

美国国家卫生研究院;

关键词：

CYTOCHROME-P450; 2D6; CYP2D6; GENOTYPE; BETA-BLOCKERS; METOPROLOL METABOLISM; MAJOR DETERMINANT; POLYMORPHISM; PHENOTYPE; FAILURE; GRK5; PHARMACOKINETICS;

D O I：

10.1016/j.trsl.2009.07.010

中图分类号：

R446 [实验室诊断]; R-33 [实验医学、医学实验];

学科分类号：

1001 ;

摘要：

Pharmacogenetics is the study of gene-drug interactions. In the post-Human Genome era, and with the realization that personal genotypes differ by millions of bases (gene polymorphisms), the application of genetics to explain interindividual differences in clinical drug response seems to offer great promise. Here, recent basic and translational developments in pharmacogenetic profiling of beta-blocker response in heart failure are reviewed in the context of the possible consequences of such advances on drug development and clinical therapeutics. (Translational Research 2009; 154:295-302)

引用

页码：295 / 302

页数：8

共 42 条

[1] Genetic Variation in the CYP2D6 Gene Is Associated With a Lower Heart Rate and Blood Pressure in β-Blocker Users [J].

Bijl, M. J. ;

Visser, L. E. ;

van Schaik, R. H. N. ;

Kors, J. A. ;

Witteman, J. C. M. ;

Hofman, A. ;

Vulto, A. G. ;

van Gelder, T. ;

Stricker, B. H. Ch .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2009, 85 (01) :45-50

[2] The impact of the CYP2D6 polymorphism on haloperidol pharmacoldnetics and on the outcome of haloperidol treatment [J].

Brockmöller, J ;

Kirchheiner, J ;

Schmider, J ;

Walter, S ;

Sachse, C ;

Müller-Oerlinghausen, B ;

Roots, I .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2002, 72 (04) :438-452

[3] β-blockers in congestive heart failure -: A Bayesian meta-analysis [J].

Brophy, JM ;

Joseph, L ;

Rouleau, JL .

ANNALS OF INTERNAL MEDICINE, 2001, 134 (07) :550-560

[4] The Arg389GIy beta1-adrenoceptor polymorphism and catecholamine effects on plasma-renin activity [J].

Bruck, H ;

Leineweber, K ;

Ternme, T ;

Weber, M ;

Heusch, G ;

Philipp, T ;

Brodde, OE .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2005, 46 (11) :2111-2115

[5] Comparison of two CYP2D6 genotyping methods and assessment of genotype-phenotype relationships [J].

Chou, WH ;

Yan, FX ;

Robbins-Weilert, DK ;

Ryder, TB ;

Liu, WW ;

Perbost, C ;

Fairchild, M ;

de Leon, J ;

Koch, WH ;

Wedlund, PJ .

CLINICAL CHEMISTRY, 2003, 49 (04) :542-551

[6]

CRESCI S, J AM COLL C IN PRESS

[7] The mechanistic imperative for pharmacogenomics [J].

Dorn, Gerald W., II ;

Cresci, Sharon .

PHARMACOGENOMICS, 2008, 9 (07) :801-803

[8]

Eichhorn E, 2001, NEW ENGL J MED, V344, P1659

[9] Comparison of the beneficial effect of beta-blockers on mortality in patients with ischaemic or non-ischaemic systolic heart failure: A meta-analysis of randomised controlled trials [J].

Fauchier, Laurent ;

Pierre, Bertrand ;

de Labriolle, Axel ;

Babuty, Dominique .

EUROPEAN JOURNAL OF HEART FAILURE, 2007, 9 (11) :1136-1139

[10] Impact of CYP2D6 genotype on adverse effects during treatment with metoprolol:: A prospective clinical study [J].

Fux, R ;

Mörike, K ;

Pröhmer, AMT ;

Delabar, U ;

Schwab, M ;

Schaeffeler, E ;

Lorenz, G ;

Gleiter, CH ;

Eichelbaum, M ;

Kivistö, KT .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2005, 78 (04) :378-387

← 1 2 3 4 5 →